Feb 22, 2021 — 3 min read
Our demo website (https://insight.lunit.io/) for Lunit INSIGHT CXR and Lunit INSIGHT MMG has over 2,000 users around the world. With the pandemic, more and more users are trying our AI solutions online and contacting us for further product information.
Recently, we received a delightful email from one of our users. Prof. M. Erkin Aribal, M.D., from the Acibadem MAA University in Turkey, conducted his research on the potential clinical value of Lunit INSIGHT MMG using our demo website. And his study has been accepted as a recorded presentation to the European Congress of Radiology 2021.
For a sneak preview of his presentation, check out his email interview below. He kindly explained to us how he planned his research using our demo website, and what he has found out from his study.
How did you come across our demo website?
I met Lunit during the Radiological Society of North America 2019. During my meeting at Lunit booth, I was introduced to the online demo website. I figured I could develop my idea of planning a study with breast cancers in the screening project that we had organized for five districts in Istanbul county.
Tell us about your experience with our demo website.
The website was easy-to-use and user-friendly. The AI result appeared very fast and highlighted areas of concern in colors, indicating the probability of the existence of the finding.
What did you aim to achieve from your study and how did you design it?
We aimed to evaluate the diagnostic performance of the AI algorithm in detecting breast cancers, particularly missed and interval cancers. We prepared for datasets of screening mammograms consisting of normal mammograms, and mammograms with screen detected, including missed and interval breast cancers. And those images were retrieved from PACS.
What is the key takeaway of your study?
The AI algorithm reached AUC levels between 0.840 to 0.903, a similar accuracy rate to that of radiologists. It successfully detected a number of missed and interval breast cancers. The finding suggests that Lunit AI certainly has the potential to augment the diagnostic performance of breast cancer detection as a second reader.
How is the breast screening environment in Turkey?
The breast cancer rate below age 50 is quite high in Turkey. The national breast screening program starts at age 40. Two readers interpret mammograms and a third reader is assigned for inconsistencies.
We have three drawbacks to mammography screening. First of all, lack of experienced breast specialists is a major limitation. Secondly, the low participation rate of women to the national screening program hinders interval breast cancer detection. The participation rate is as low as 15%, especially in rural areas. A majority of women have their screening mammogram for only once in their lifetime. Thirdly, dense mammograms account for 45% of the entire screening mammograms, which causes low sensitivity in breast cancer detection.
How would AI help Turkish radiologists improve their diagnostic performance of breast cancer detection?
As mentioned above, the lack of experienced breast specialists and the importance of having a low rate of interval cancers requires meticulous and accurate breast cancer detection in the national screening program.
Lunit AI proved to detect a number of missed and interval breast cancers and to be efficient as a second reader in our study. It will help radiologists increase their reading speed and accurately interpret abnormal mammograms.
Do you have any other plans to conduct research using AI?
We are planning to conduct further studies where AI is used in decision-making for other imaging procedures such as ultrasound and tomosynthesis.
Using AI to better manage COVID-19
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Uncertainty and Deep Learning
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI